What is Noxilizer?
Noxilizer operates at the intersection of material science and pharmaceutical manufacturing, providing ultra-low temperature nitrogen dioxide sterilization technology. By addressing the critical need for safe, effective sterilization of temperature-sensitive products—such as prefilled syringes, sensors, and orthopedic implants—the company ensures drug integrity and supply chain efficiency. Their dual-model approach, offering both specialized equipment and contract sterilization services, allows them to cater to a diverse range of manufacturers who require high-precision, regulatory-compliant sterilization methods. As the life sciences industry faces increasing pressure to maintain product stability, Noxilizer's innovative process serves as a key enabler for modern medical device and drug delivery systems.
How much funding has Noxilizer raised?
Noxilizer has raised a total of $30.5M across 3 funding rounds:
Debt
$150K
Debt
$350K
Other Financing Round
$30M
Debt (2020): $150K with participation from PPP
Debt (2021): $350K led by PPP
Other Financing Round (2025): $30M supported by NewVale Capital
Key Investors in Noxilizer
NewVale Capital
NewVale Capital is a growth equity investment firm focused on investing in established, revenue-generating businesses within the life sciences sector, aiming to support the delivery of next-generation medicines.
PPP
Public-Private Partnership
What's next for Noxilizer?
With this recent capital injection, Noxilizer is well-positioned to scale its operations and expand its footprint within the global life sciences ecosystem. The strategic focus will likely shift toward enhancing service architecture and increasing capacity to meet the rising demand for specialized sterilization. By leveraging this investment, the company aims to accelerate the adoption of its technology, further cementing its role as an essential partner for manufacturers navigating complex regulatory environments and demanding product requirements. Future growth will be driven by the continued integration of their sterilization solutions into the broader pharmaceutical supply chain, ensuring that the next generation of medical products reaches patients with maximum safety and efficacy.
See full Noxilizer company page
